MAP2K7 and pancreatic ductal adenocarcinoma: Of clinical relevance, off-label treatment of a patient with metastatic pancreatic ductal adenocarcinoma with the MEK inhibitor trametinib plus hydroxychloroquine (a lysosomotropic agent for autophagy blockage) resulted in 50% shrinkage in tumor burden without any adverse effects [166].